{"id":"chf6001-dpi","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dysphonia"},{"rate":"null","effect":"Upper respiratory tract infection"}]},"_chembl":{"chemblId":"CHEMBL146100","moleculeType":"Small molecule","molecularWeight":"193.21"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by relaxing the airway muscles to improve lung function in patients with chronic obstructive pulmonary disease (COPD). CHF6001 DPI is designed to provide sustained bronchodilation and improve symptoms in patients with COPD.","oneSentence":"CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:07:56.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD)"}]},"trialDetails":[{"nctId":"NCT04636814","phase":"PHASE3","title":"A 52-week, Placebo- and Active- Controlled (Roflumilast, Daliresp® 500µg) Study to Evaluate the Efficacy and Safety of Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis. (PILLAR)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-07-12","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":3973},{"nctId":"NCT06029595","phase":"PHASE2","title":"Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2023-11-26","conditions":"Uncontrolled Asthma","enrollment":517},{"nctId":"NCT04636801","phase":"PHASE3","title":"A 52-week, Placebo-controlled Study to Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With COPD and Chronic Bronchitis (PILASTER)","status":"TERMINATED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-07-14","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":4710},{"nctId":"NCT06900816","phase":"PHASE2","title":"A Comparison Study Between Adolescents With Asthma and Adults With Asthma on How They Absorb, Metabolise and Eliminate CHF 6001","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-03-28","conditions":"Asthma","enrollment":50},{"nctId":"NCT06892756","phase":"PHASE1","title":"Effect of Cyclosporine Drug Interaction on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers. Drug-Drug Interaction 2 (DDI2) Study","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2025-03-18","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":30},{"nctId":"NCT06395610","phase":"PHASE1","title":"Effect of Erythromycin on the Absorption, Metabolism and Elimination of CHF6001 in Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2024-03-28","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT05373953","phase":"PHASE1","title":"Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-05-05","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT04756960","phase":"PHASE1","title":"Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-03-10","conditions":"Chronic Obstructive Pulmonary Disease (COPD), COPD","enrollment":8},{"nctId":"NCT05431426","phase":"PHASE1","title":"PK of CHF6001 in Subjects With Mild, Moderate and Severe Renal Impairment vs. Healthy Volunteers","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2022-07-29","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":44},{"nctId":"NCT04739774","phase":"PHASE1","title":"Investigation of the Effect of Inhibition of CYP3A4/5 by Itraconazole on the PK of CHF6001 (Tanimilast)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2021-02-22","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":24},{"nctId":"NCT03004417","phase":"PHASE2","title":"Pharmacodynamics, Pharmacokinetics and Safety of Two Doses of CHF6001 DPI in Subjects With Moderate, Severe COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-10-31","conditions":"COPD","enrollment":61},{"nctId":"NCT01703052","phase":"PHASE1","title":"Safety and Tolerability of Inhaled CHF 6001 in Healthy Volunteers (HV)","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2011-07","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":74},{"nctId":"NCT02986321","phase":"PHASE2","title":"A 24-wk Dose Ranging Study to Evaluate the Efficacy and Safety of 4 Doses of a New PDE4 Inhibitor in Patients With COPD","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2016-12-15","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1130},{"nctId":"NCT01689571","phase":"PHASE2","title":"A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-10","conditions":"Asthma","enrollment":36},{"nctId":"NCT01730404","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of 28-day Inhaled CHF 6001 DPI in COPD Patients","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2012-10","conditions":"COPD","enrollment":55},{"nctId":"NCT02119247","phase":"PHASE1","title":"Study to Investigate the Pharmacokinetics of CHF 6001 DPI Administered Via Nexthaler® Device or the Capsule for Oral Inhalation Via Aerolizer® Device","status":"COMPLETED","sponsor":"Chiesi Farmaceutici S.p.A.","startDate":"2014-04","conditions":"COPD","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CHF6001 DPI","genericName":"CHF6001 DPI","companyName":"Chiesi Farmaceutici S.p.A.","companyId":"chiesi-farmaceutici-s-p-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHF6001 DPI is a dry powder inhaler formulation of a long-acting muscarinic antagonist. Used for Chronic obstructive pulmonary disease (COPD).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}